MetabolAite research program
MetabolAite applies AI to metabolic intelligence, diabetes-oriented modeling, molecular hypotheses and systems-level biomedical reasoning.
The project links metabolism, molecular simulation, literature intelligence and candidate intervention analysis through a computational pipeline.
MetabolAite
AI curing diabetes
PROBABILISTIC GENOMICS
MASSIVE AI-GENERATED MUTATIONS THROUGH PREDICTIVE MODELS
GENERATION OF VIRTUAL MOLECULES AND MicroRNA FOR FIGHTING VIRUSES, CANCERS, ENHANCING HUMAN GENOMES, DISCOVERING AND VALIDATING DRUGS
MetabolAite
PROBABILISTIC GENOMICS
MASSIVE AI-GENERATED MUTATIONS THROUGH PREDICTIVE MODELS
GENERATION OF VIRTUAL MOLECULES AND MicroRNA FOR FIGHTING VIRUSES, AMR, CANCERS, ENHANCING HUMAN GENOMES, DISCOVERING AND VALIDATING DRUGS
MetabolAite by Transhumangene
MetabolAite
Eggenhöffner Roberto, Professor, Physicist at Department of Integrated Surgical and Diagnostic Sciences (DISC) University of Genoa, Head of the Research Group in Medical Biophysics & Lab
DIABETES
Diabetes represents a serious and challenging public health concern, the magnitude of which has more than doubled within the last decades, due to:
demographic changes (population growth and aging);
adoption of western, unhealthy lifestyles and habits, including low-quality food and lack of physical activity, has resulted in a pandemic of obese individuals.
WHY NOW?
This increase results in an unprecedented surge of diabetes cases that is absorbing a lot of economic and financial resources imposing a dramatically relevant societal burden.
If not counteracted, this surge could critically stress health systems. Moreover, not all diabetes phenotypes are the same and should receive a personalized treatment.
THE PROMISED LAND
Elucidating the mechanisms underlying diabetes and finding optimal treatment options can lead to better, personalized control of the disease, leading to cost-effective therapies and considerably saving resources. Moreover, individualized, tailored management instead of a one-size-fits-it-all approach can increase patient compliance and improve outcomes.
WHICH ARE THE OBSTACLES
Of course, considerable achievements have been pursued in diabetology, but if we consider specific settings, genetic mechanisms have not been fully elucidated yet. This is especially true in contexts when relationships among siblings happen more often than in other realities.
Some obstacles to a diabetes-free world population include:
Most people think that the currently available drugs can be taken a lifetime. It makes little, if no sense at all, to try to "eradicate" diabetes by genetic techniques, such as immunization or another kind of AI-generated drugs. In other words, they prefer to live together with the disease and cope with it, rather than to defeat it forever
People also think that these new techniques may be costly and they could not afford them
People believe these drugs are enough to manage diabetes, being genetic and individual aspects negligible
WHAT WE HAVE DONE SO FAR
We have already successfully crystallized an insulin sequence, with an excellent resolution, one of the highest obtained results. This enables us to shed more light on the mechanisms of insulin action at a cellular and molecular level, studying its genetic variants and the primary pathogenic mechanisms leading to diabetes.
Business Plan The Numbers
Financial Request & Costs for Seed
Breakeven Point & Business Model
The B.E.P. will be reached between 12 - 15 months
Our Markets: Big & Small Pharma, Universities & National Health institutions and Hospitals & Clinics
Business Model:
most of the products are in the form of a hybrid Pay per service (DownPayment + Results + prototype selling)
We want to write the words «the end» to diabetes disease by AI-generated drugs: gene therapies and vaccines